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Abstract 
The transforming growth factor-β superfamily signaling pathway is thought to be 
involved in the pathogenesis of pulmonary arteriovenous malformation (PAVM). 
However, the association between bone morphogenetic protein receptor type 2 
(BMPR2) gene mutations and PAVM remains unclear. We present a case of concurrent 
PAVM and pulmonary arterial hypertension (PAH), with a deletion mutation in exon 6 
and exon 7 of the BMPR2 gene. Drug treatment for PAH improved the patient’s 
hemodynamics and exercise capacity, but worsened oxygenation. This case suggests 
that BMPR2 gene mutation may be associated with the complex presentation of PAVM 
combined with PAH.  
 
Keywords: ambrisentan, bone morphogenetic protein receptor type 2, pulmonary 
arterial hypertension, pulmonary arteriovenous malformation, sildenafil 
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Abbreviation list 
ACVRL1 = activin A receptor type 2-like 1 
BMP = bone morphogenetic protein  
BMPR2 = bone morphogenetic protein receptor type 2  
CI = cardiac index  
CO = cardiac output  
MADH4 = decapentaplegic homologue 4 
ENG = endoglin 
HHT = hereditary hemorrhagic telangiectasia  
HRCT = high resolution computed tomography 
MADH4 = decapentaplegic homologue 4  
PAH = pulmonary arterial hypertension  
PAP = pulmonary artery pressure  
PAVM = pulmonary arteriovenous malformation  
PCWP = pulmonary capillary wedge pressure 




RHC = right heart catheterization  
TGF-β = transforming growth factor-β  
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1. Introduction 
Hereditary pulmonary arterial hypertension (PAH) and hereditary hemorrhagic 
telangiectasia (HHT) are associated with mutations in the transforming growth factor-β 
(TGF-β) and bone morphogenetic protein (BMP) pathways and have a major impact on 
lung vasculature [1, 2]. Pulmonary arteriovenous malformation (PAVM) is a 
complication of HHT, occurring in 20–40% of patients. Conversely, approximately 
80–95% of PAVM cases are associated with HHT [3]. The most frequent cause of 
hereditary PAH is bone morphogenetic protein receptor type 2 (BMPR2) gene mutation. 
However, its association with HHT or PAVM remains unclear. We present a case of 
concurrent PAVM and PAH, with a novel deletion mutation in exon 6 and exon 7 of the 
BMPR2 gene.  
 
2. Case report 
A 33-year-old woman was referred to a clinic due to cough, where she was found to 
have a chest CT abnormality. At presentation in our hospital, she had no chest 
symptoms. Physical examination revealed a body temperature of 36.5°C, blood pressure 
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of 116/78 mmHg, and pulse rate of 80 beats/min with a regular rhythm. Heart and lung 
auscultation revealed no abnormalities, and there was no pretibial edema. There was no 
sign of mucocutaneous telangiectases on the fingers, lips, or oral cavity. Additionally, 
there was no previous history of drug abuse. Moreover, there was no family history of 
HHT, recurrent nasal hemorrhage, or abnormal chest shadow. Laboratory tests showed 
mild polycythemia, and autoantibody screening for collagen vascular diseases was 
negative. Electrocardiography and arterial blood gas at rest revealed no abnormalities. 
Pulmonary function tests showed decreased diffusing capacity (supplementary Table 
S1). Chest HRCT revealed meandering vasculature in bilateral lung fields (Fig. 1A). A 
3-dimensional reconstruction image showed a saccular aneurysm with an afferent artery 
and efferent vein, suggesting the presence of PAVM (Fig. 1B). Tc MAA scintigraphy 
and the 100% oxygen inhalation method showed a mild increase in the arteriovenous 
shunt ratio (8.4% and 5.1%, respectively), and contrast echocardiography revealed 
microbubble flow from the pulmonary vein to the left atrium, such that LA 
enhancement was delayed from RA enhancement by more than 3 cardiac cycles. Based 
on these findings, the patient was diagnosed with multiple PAVMs. Abdominal CT and 
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brain MRI showed no AVM in other organs, and portal hypertension was ruled out by 
abdominal echocardiogram. According to the International Clinical Diagnostic Criteria 
for HHT, a diagnosis of HHT was unlikely [4].
 
 
Right heart catheterization (RHC) revealed concurrent pulmonary arterial 
hypertension as follows: pulmonary artery pressure (PAP) 55/29 (41) mmHg, 
pulmonary capillary wedge pressure (PCWP) 14 mmHg, cardiac output (CO) 3.81 




resistance (PVR) 7.1 
Wood. A series of examinations showed no evidence of left-sided heart failure, 
pulmonary embolism, obstructive or restrictive pulmonary disease, portal hypertension, 
or connective tissue disease. Mutation analysis of entire coding exons and adjacent 
introns of the BMPR2, endoglin (ENG), activin A receptor type 2-like 1 (ACVRL1), and 
decapentaplegic homologue 4 (MADH4) genes was performed by bidirectional direct 
DNA sequencing after PCR amplification of genomic DNA. Analysis of large-scale 
gene rearrangements in BMPR2, ENG, and ACVRL1 was performed using multiplex 
ligation-dependent probe amplification. This genetic study was approved by the ethics 
committees of the National Cerebral and Cardiovascular Center Research Institute 
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(approval number M20-01-3, November 17, 2011). No ACVRL1 or ENG mutation was 
identified. However, a heterogeneous germline deletion mutation of exon 6 and exon 7 
of the BMPR2 gene was identified, which was further confirmed by real-time 
quantitative PCR using TaqMan probes.  
Because the patient was asymptomatic, she was followed-up without any 
specific treatment. The patient experienced mild dyspnea after she delivered a child 16 
months after the diagnosis of PAVM and PAH. Follow up RHC showed worsening of 
PH (PAP 81/41 (56) mmHg, PCWP 14 mmHg, CO 3.59 L/min, CI 2.60 L/min/m
2
, PVR 
10.9 Wood), although the shunt ratio was unchanged (Fig. 2). PAH-specific treatment 
with sildenafil (60 mg/day) and ambrisentan (5–10 mg/day) improved hemodynamics, 
exercise capacity, and symptoms, although oxygenation at rest and during exercise 
deteriorated, accompanied by mild elevation of the shunt ratio (Fig. 2). At present, the 





We presented a case of PAVM combined with PAH, with a BMPR2 gene mutation. The 
diagnosis of PAVM was made based on compatible findings of chest HRCT and contrast 
echocardiography along with an increased shunt ratio. There was no other comorbidity 
likely to cause PAVM, suggesting that PAVM was associated with the BMPR2 gene 
mutation. Aside from PAVM, this patient had no features suggestive of HHT. However, 
because of the relatively young age of the patient, it is possible that HHT will develop 
in the future. Because the clinical phenotype of HHT becomes easier to identify with 
age, the age of onset in a Japanese cohort was reported to be >30 years in 27% of 
patients and >40 years in 8% of patients [5]. 
Although PAH and HHT have different characteristics with regard to 
endothelial cell and smooth muscle cell proliferation, they may share common genetic 
backgrounds [1, 2, 6]. Mutations in the BMPR2 gene have been associated with 80% of 
familial PAH and 15–40% of idiopathic PAH cases, whereas about 80% of HHT cases 
are associated with heterozygous germline mutations of ENG, ACVRL1, and MADH4 [1, 
3]. Approximately 30 families with both PAH and HHT have been described, and most 
of them carried ACVRL1 gene mutations [2, 6, 7, 8].
 
To date, there has been only one 
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case report of a patient with a BMPR2 mutation who had concurrent PAH and HHT with 
PAVM [9]. The present case, along with the previous case, suggests that BMPR2 gene 
mutation may be associated with the complex presentation of PAVM combined with 
PAH. Additionally, pre-existing PAH may have caused the PAVM. In previous reports of 
concurrent PAH and PAVM, the authors speculated that PAH may have caused PAVM 
by rupture of the hypoplastic vascular septa, an increase in the size of a previously 
developed arteriovenous fistula, or an enlargement of anatomically normal 
arteriovenous shunts [10, 11]. Unfortunately, genetic abnormalities were not 
investigated in these reports. 
It remains unknown why gene mutations of common pathways cause different 
phenotypes, and why the two phenotypes co-exist in a subset of cases. It is speculated 
that differential distribution of the receptors and alternative ligand-receptor responses 
may play a role [1, 12]. BMP9 acts through ACVRL1 and SMAD1, 5, 8, and the signal 
is balanced by BMPR2 and ActR2A [12]. BMPR2 gene mutation does not usually lead 
to overt HHT, because ActR2A compensates. It is speculated that in patients with HHT 
and BMPR2 gene mutation, this compensation may be incomplete [9]. In our patient, 
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the entire genomic deletion of exon 6 and exon 7 of the BMPR2 gene, containing 231 bp 
and 115 bp of the coding sequence, respectively, would result in a frame shift transcript 
lacking 346 bp of the coding sequence, including the region coding for the kinase 
domain. The mutated transcript is expected to be degraded by nonsense-mediated 
mRNA decay, which supposedly leads to haploinsufficiency of the BMPR2 gene 
product. This mutation has not been reported in the literature so far, and differs from 
that reported previously in concurrent HHT and PAH (nonsense mutation in exon 10) 
[9]. Further investigation is necessary to elucidate mechanisms by which these 
mutations cause both PAVM and PAH. 
In the present case, PAH worsened after the delivery of a child. After the 
diagnosis of PAVM and PAH, we instructed the patient regarding the risks of becoming 
pregnant, such as an enlargement of the PAVM and increased risk of pulmonary 
hemorrhage and cerebrovascular events [13, 14]. Additionally, PAH during pregnancy is 
associated with a high risk to the parturient [15]. Because of the risk posed by PAVM 
and PAH, we believe that pregnancy should be avoided in this situation. 
The patient had no hypoxemia during rest, whereas oxygen desaturation was 
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observed on exercise. This may be due to a small increase in the shunt ratio at rest, and 
the shunt ratio and ventilation/perfusion mismatch may have increased during exercise 
because of the increased vascular resistance of the pulmonary arteries. Regarding the 
medical treatment of patients with PAVM and PAH, some authors do not recommend 
vasodilator therapy because of a potential increase of arteriovenous shunt volume, while 
others have demonstrated the effectiveness and safety of endothelin receptor antagonists 
in this disease [16, 17]. In our case, combination therapy improved exercise capacity 
and hemodynamics, though oxygenation deteriorated, with a mild increase of the shunt 
ratio. One possible explanation is that the increased shunt ratio caused by the 
vasodilator worsened hypoxemia, whereas the drug decreased pulmonary vascular 
resistance, leading to increased cardiac output and improved exercise capacity. Taking 
the potential adverse effect on shunt ratio into account, careful follow-up of 
oxygenation is required when PAH-specific therapy is applied to patients with PAVM 
and PAH. 
In conclusion, PAVM and PAH can occur in association with germline BMPR2 
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Figure 1. A. Chest HRCT on admission. Multiple meandering feeding vessels (arrows) 
are found in bilateral lung fields. B. 3-dimentional reconstruction image of chest CT. A 
saccular aneurysm (5.8 mm in diameter, arrowhead) with an afferent artery (2.6 mm in 
diameter) and efferent vein (2.7 mm in diameter) is shown (arrows). PA, pulmonary 
artery; PV, pulmonary vein; AA, afferent artery; EV, efferent vein. 
 
Figure 2. Clinical course of the patient. PH deteriorated after the delivery of a child. 
After 5 months of combination treatment for PH, hemodynamics and clinical symptoms 
improved. *Period from the start of PAH treatment. NYHA-FC, New York Heart 
Association Functional Class; sPAP, systolic pulmonary artery pressure estimated by 
Doppler echocardiogram; PAP, pulmonary artery pressure measured by right heart 
catheter; CI, cardiac index; PVR, pulmonary venous resistance; BNP, B-type natriuretic 
peptide; 6MWD, six-minute walk distance; Min SpO2, Minimal oxygen saturation 
during six-minute walk test. 


Table S1. Laboratory test results on admission
<CBC>                            
White blood cells     4.6 × 10
9
/L     
Red blood cells          4.78 × 10
12
/L  
Hemoglobin               15.2 g/dL 




PT (sec)  11.6 s 
PT (act)  100% 
APTT  27.2 s 
Fib  245 mg/dL  
D-dimer  0.2 pg/mL 
<Serology>   
CRP  0.0 mg/dL     
Anti-nuclear antibody  <×40   
Anti-CCP antibody negative 
Anti-centromere antibody     negative                       
Anti-Scl-70 antibody negative 
Anti-RNP antibody  negative 
<Biochemistry> 
LDH (129–241) 184 IU/L  
CPK (35–141) 69 IU/L 
TP (6.3–8.1)   7.2 g/dL 
- globulin (10.6–20.5)  15.2%  
<Arterial blood gas (room air)> 
pH  7.401 
PaO2   81.9 mmHg 
PaCO2  40.2 mmHg 
HCO3
-
  24.4 mmol/L 
BE  0.2 mEq/L 
<Pulmonary function tests> 
%VC  80.1% 
%FEV1  75.5% 
FEV1/FVC             87.9% 
%DLCO                 56.9% 
%DLCO /VA 80.5% 
abbreviations: APTT, activated partial thromboplastin time; CCP, cyclic citrullinated 
peptide; RNP, ribonucleoprotein; LDH, lactate dehydrogenase; CPK, creatine 
phosphokinase; PT, prothrombin time; TP, total protein; VC, vital capacity; FEV, 
forced expiratory volume; FVC, forced vital capacity; DLCO, diffusing capacity for 
carbon monoxide. 
